AR101871A1 - Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos - Google Patents
Composiciones de glicoconjugado inmunogénico / terapéutico y sus usosInfo
- Publication number
- AR101871A1 AR101871A1 ARP150102941A ARP150102941A AR101871A1 AR 101871 A1 AR101871 A1 AR 101871A1 AR P150102941 A ARP150102941 A AR P150102941A AR P150102941 A ARP150102941 A AR P150102941A AR 101871 A1 AR101871 A1 AR 101871A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- klh
- portions
- globe
- covalently linked
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 1
- 241000237852 Mollusca Species 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 108060003552 hemocyanin Proteins 0.000 abstract 2
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 abstract 1
- 101150096822 Fuca1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición caracterizada porque comprende una pluralidad de porciones de Globo H covalentemente ligadas a uno a veinte (n = 1 a 20) porción/porciones de hemocianina extraída del molusco llamado lapa californiana (KLH) donde las porciones de Globo H están covalentemente ligadas a las porciones KLH en uno o más residuos aminoácidos. Reivindicación 28: La composición de la reivindicación 1, caracterizada porque la porción Globo H comprende (Fuca1®2 Gab1®3 GalNAcb1®3 Gala1®4 Galb1®4 G1c). Reivindicación 29: La composición de la reivindicación 1, caracterizada porque la subunidad de porción KLH pertenece al Nº ID DE SEC. 1. Reivindicación 37: La composición de la reivindicación 1, caracterizada porque la porción Globo H covalentemente ligada a una subunidad de porción de hemocianina extraída del molusco llamado lapa californiana (KLH) está ligada mediante un enlace 4-(4-N-maleimidometil) ciclohexano-1-carboxil hidracida (MMCCH). Reivindicación 46: Un método para tratar el cáncer en un paciente que necesita dicho tratamiento, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de la composición de la reivindicación 1. Reivindicación 49: Un método para inducir anticuerpos en un sujeto que tiene la finalidad de crear anticuerpos monoclonales para uso terapéutico y diagnóstico caracterizado porque comprende administrar al sujeto, una cantidad eficaz de la composición de la reivindicación 1. Reivindicación 51: Una composición farmacéutica caracterizada porque comprende (a) una pluralidad de porciones de Globo H covalentemente ligado a una o más Subunidades de porción KLH; y (b) un adyuvante de a-galactosil-ceramida (a-GalCer). Reivindicación 52: La composición de la reivindicación 51, caracterizada porque el adyuvante a-GalCer tiene la estructura de fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050567P | 2014-09-15 | 2014-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101871A1 true AR101871A1 (es) | 2017-01-18 |
Family
ID=55533765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102941A AR101871A1 (es) | 2014-09-15 | 2015-09-15 | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160339089A1 (es) |
| EP (1) | EP3193919B1 (es) |
| JP (1) | JP6774941B2 (es) |
| KR (2) | KR20230109783A (es) |
| CN (1) | CN107427564A (es) |
| AR (1) | AR101871A1 (es) |
| AU (1) | AU2015317889B2 (es) |
| BR (1) | BR112017005120B1 (es) |
| CA (1) | CA2961522A1 (es) |
| CL (1) | CL2017000625A1 (es) |
| ES (1) | ES2797747T3 (es) |
| IL (1) | IL251120B (es) |
| MY (1) | MY188880A (es) |
| PH (1) | PH12017500478A1 (es) |
| RU (1) | RU2720295C2 (es) |
| SG (1) | SG11201702037SA (es) |
| TW (1) | TWI726850B (es) |
| WO (1) | WO2016044326A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CA3019560A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| SG11201809024UA (en) * | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| CA3032049C (en) | 2016-07-27 | 2023-11-07 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
| AU2017361549B2 (en) | 2016-11-21 | 2023-12-21 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| WO2019217951A1 (en) * | 2018-05-11 | 2019-11-14 | Obi Pharma Inc. | Method for predicting human immune response |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
| CA2454853A1 (en) * | 2001-08-14 | 2003-02-27 | Biomira, Inc. | Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier |
| WO2010005735A2 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| KR101677279B1 (ko) * | 2009-06-16 | 2016-11-29 | 아카데미아 시니카 | 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신 |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| CA3044471C (en) * | 2013-01-04 | 2021-05-11 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| CA2924286C (en) * | 2013-09-17 | 2022-06-21 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
-
2015
- 2015-09-15 SG SG11201702037SA patent/SG11201702037SA/en unknown
- 2015-09-15 CN CN201580062962.2A patent/CN107427564A/zh active Pending
- 2015-09-15 MY MYPI2017000385A patent/MY188880A/en unknown
- 2015-09-15 WO PCT/US2015/050270 patent/WO2016044326A1/en active Application Filing
- 2015-09-15 KR KR1020237023433A patent/KR20230109783A/ko not_active Application Discontinuation
- 2015-09-15 RU RU2017112982A patent/RU2720295C2/ru active
- 2015-09-15 BR BR112017005120-6A patent/BR112017005120B1/pt active IP Right Grant
- 2015-09-15 AR ARP150102941A patent/AR101871A1/es unknown
- 2015-09-15 KR KR1020177009879A patent/KR20170090405A/ko active IP Right Grant
- 2015-09-15 US US14/855,260 patent/US20160339089A1/en active Pending
- 2015-09-15 EP EP15842660.1A patent/EP3193919B1/en active Active
- 2015-09-15 AU AU2015317889A patent/AU2015317889B2/en active Active
- 2015-09-15 JP JP2017514552A patent/JP6774941B2/ja active Active
- 2015-09-15 ES ES15842660T patent/ES2797747T3/es active Active
- 2015-09-15 TW TW104130500A patent/TWI726850B/zh active
- 2015-09-15 CA CA2961522A patent/CA2961522A1/en active Pending
-
2017
- 2017-03-13 IL IL251120A patent/IL251120B/en active IP Right Grant
- 2017-03-13 PH PH12017500478A patent/PH12017500478A1/en unknown
- 2017-03-14 CL CL2017000625A patent/CL2017000625A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201628646A (zh) | 2016-08-16 |
| KR20230109783A (ko) | 2023-07-20 |
| BR112017005120A2 (pt) | 2018-01-23 |
| RU2017112982A (ru) | 2018-10-17 |
| KR20170090405A (ko) | 2017-08-07 |
| EP3193919A1 (en) | 2017-07-26 |
| CL2017000625A1 (es) | 2018-02-02 |
| EP3193919B1 (en) | 2020-04-08 |
| MY188880A (en) | 2022-01-12 |
| CN107427564A (zh) | 2017-12-01 |
| ES2797747T3 (es) | 2020-12-03 |
| PH12017500478A1 (en) | 2017-07-10 |
| US20160339089A1 (en) | 2016-11-24 |
| EP3193919A4 (en) | 2018-04-18 |
| JP2017532310A (ja) | 2017-11-02 |
| AU2015317889A1 (en) | 2017-04-13 |
| RU2017112982A3 (es) | 2019-04-24 |
| SG11201702037SA (en) | 2017-04-27 |
| IL251120A0 (en) | 2017-04-30 |
| RU2720295C2 (ru) | 2020-04-28 |
| WO2016044326A1 (en) | 2016-03-24 |
| WO2016044326A9 (en) | 2017-05-11 |
| AU2015317889B2 (en) | 2021-06-03 |
| JP6774941B2 (ja) | 2020-10-28 |
| BR112017005120B1 (pt) | 2021-01-05 |
| IL251120B (en) | 2021-05-31 |
| TWI726850B (zh) | 2021-05-11 |
| CA2961522A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| CO2017007293A2 (es) | Dinucleótidos cíclicos útiles para el tratamiento de (inter alia) cáncer | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| DOP2016000316A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| PE20181049A1 (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| CO6970607A2 (es) | Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo | |
| AR110567A1 (es) | Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina) | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| CL2021002582A1 (es) | Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112018068960A2 (pt) | formulações de enalapril |